Based on these results, the FDA (Food and Drug Administration) and the TFDA (Taiwan Food and Drug Administration) approved nivolumab plus chemotherapy in patients with advanced/metastatic esophageal/GEJC/gastric cancer independent from PD-L1 CPS status in the USA and Taiwan, respectively. The gene discussed is CD274; the disease is gastric cancer.